arrow
S

Sandra P. D'Angelo

Memorial Sloan Kettering Cancer Center
H指数:52
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma

在去分化脂肪肉瘤中序贯使用CDK4/6和PD-1抑制剂后的肿瘤与免疫动态变化:一项2期研究的结果

2026-02-010
PRE
A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcoma

一项关于CSF1R抑制剂vimseltinib与PD-L1抑制剂avelumab联合治疗晚期肉瘤的I期研究

2025-07-250
OAAI
Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies

I期IMCnyeso研究,该研究是一种靶向NY-ESO-1表达性恶性病变的T细胞受体双特异性ImmTAC。

2025-04-010
OAAI
Immunologic correlates in a CIC::DUX4 fusion-positive sarcoma responsive to dual immune checkpoint blockade

免疫学相关指标在一例对双重免疫检查点阻断敏感的CIC::DUX4融合阳性肉瘤中的表现

2025-03-250
OA
A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses
2024-09-280
OAAI
Peripheral blood (PB) T cell phenotype and tumor microenvironment (TME) subtype are independently associated with immune checkpoint blockade (ICB) outcomes in sarcomas

外周血(PB)T细胞表型和肿瘤微环境(TME)亚型与肉瘤中免疫检查点阻断(ICB)的疗效独立相关

2024-09-010
PRE
An open label phase IIa study evaluating the preliminary efficacy of intratumoural tigilanol tiglate (TT) in advanced and/or metastatic soft tissue sarcoma (STS)

一项开放标签的IIa期研究,评估肿瘤内注射tigilanol tiglate(TT)在晚期和/或转移性软组织肉瘤(STS)中的初步疗效。

2024-09-010
PRE
Utility of circulating tumor DNA (ctDNA) as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with treatment-naive, advanced gastrointestinal stromal tumor (GIST)

循环肿瘤DNA(ctDNA)作为分子生物标志物在伊马替尼联合比尼替尼治疗初治、晚期胃肠道间质瘤(GIST)II期试验中的价值

2024-09-010
PRE
Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial

Afamitresgene autoleucel用于晚期滑膜肉瘤和粘液样圆形细胞脂肪肉瘤 (SPEARHEAD-1): 一项国际,开放标签,2期试验

LANCET
IF88.5
2024-04-0122
PRE
HLA genotyping and HLA-based clinical trial matching using MSK-IMPACT, a targeted next-generation sequencing assay
2024-03-220
PRE
Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy
2024-03-013
OA